PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Binimetinib

Drugs in development · updated 30 October 2026

Binimetinib: clinical trials and development status

Other names and codes: MEK162, Mektovi, Balimek

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 20 September 2018

As of 30 October 2026 Binimetinib is in 37 active clinical trials (recruiting or ongoing, phases I–III) for 38 diseases. The most advanced phase is III.

37Active trials
IIIMost advanced phase
38Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Binimetinib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 38 diseases.

DiseaseMost advanced phaseActive trialsReference trial
MelanomaIII18NCT04657991
Colonic neoplasmIII2NCT03803553
Skin neoplasmIII2NCT04657991
Biliary tract neoplasmIII1NCT05615818
Brain NeoplasmsII5NCT04511013
Non-small-cell lung carcinomaII4NCT04526782
MetastasisII3NCT05564377
Ovarian neoplasmII3NCT05564377
Pancreatic neoplasmII3NCT02465060
Thyroid neoplasmII3NCT02465060
Breast neoplasmII2NCT02465060
Colorectal neoplasmII2NCT02465060
Endometrial neoplasmII2NCT05564377
GliomaII2NCT02465060
Hairy cell leukemiaII2NCT04322383
Hematologic neoplasmII2NCT02465060
Lung neoplasmII2NCT02465060
LymphomaII2NCT02465060
Multiple myelomaII2NCT02465060
Triple-negative breast neoplasmII2NCT03971409
Uveal melanomaII2NCT05170334
Bladder neoplasmII1NCT02465060
CholangiocarcinomaII1NCT05564403
CraniopharyngiomaII1NCT05286788
Esophageal neoplasmII1NCT02465060
Eye neoplasmII1NCT05170334
Fallopian tube neoplasmII1NCT05564377
Gallbladder neoplasmII1NCT05564403
Gastrointestinal stromal tumorI–II1NCT01991379
Hepatocellular carcinomaII1NCT02465060

Everything on Binimetinib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch